(Q34258557)

31 July 2017

1 reference

title

Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer (English)

1 reference

31 July 2017

1 reference

1 reference

Markman M

1

1 reference

31 July 2017

publication date

1 June 2001

1 reference

Critical Reviews in Oncology Hematology

31 July 2017

published in

1 reference

31 July 2017

volume

38

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

171-175

1 reference

Intraperitoneal chemotherapy

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Clinical pharmacology of intraperitoneal cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

Pharmacokinetics of carboplatin after intraperitoneal administration

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900097-X

7 January 2021

10.1016/S1040-8428(01)00097-X

Identifiers

DOI

1 reference

31 July 2017

1 reference